Martin Lehr

Martin Lehr

Chief Executive OfficeratContext Therapeutics· In proxies 2022–2025

Pay in FY2025+45% from the year before · Context Therapeutics stock +40.0% the same year

Martin Lehr was paid $1.5M in FY2025 (Dec), up 45%. Context Therapeutics stock rose 40.0% that year.

Pay$100 in the stock at the end of FY21 → $55
Pay is from the Summary Compensation Table of each Context Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Context TherapeuticsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role -93%
  2. BioBreakPublic company
    • Director? – PresentNo stock prices for these years
  3. CureDuchenne VenturesPublic company
    • Director? – PresentNo stock prices for these years
  4. Praesidia BiotherapeuticsPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?